Paul J. Hesketh, MD
AN UPDATE of the ASCO Clinical Practice Guideline covers new medicines for nausea and vomiting related to cancer treatment. The update, issued by Hesketh et al in the Journal of Clinical Oncology,1 provides new evidence-based information on the appropriate use of olanzapine, neurokinin 1 (NK1) receptor antagonists, and dexamethasone.
“The adverse impact of inadequately controlled nausea and vomiting on patients’ quality of life is well documented,” said Paul J. Hesketh, MD, Co-Chair of the ASCO Expert Panel that developed the guideline update. “By following the ASCO Antiemetics Guideline, clinicians have the opportunity to improve patients’ quality of life by minimizing treatment-induced emesis.”
To develop this guideline, the Expert Panel conducted a systematic review of the medical literature published between November 2009 and June 2016.
Key Update Recommendations
KEY RECOMMENDATIONS of the guideline update include:
The guideline update is also available at asco.org/supportive-care-guidelines. ■
DISCLOSURE: For full disclosures of the guideline authors, visit ascopubs.org.
REFERENCE
1. Hesketh PJ, et al: J Clin Oncol. July 31, 2017 (early release online).